This morning, CVS Caremark Corp. (NYSE: CVS) reported second-quarter earnings of $966 million, or $0.75 per share, and $30.7 billion in revenue. EPS were up from $0.60 in the same period a year ago, and revenue was 16.3% higher. The Thomson Reuters consensus estimates called for $0.79 per share and $30.9 billion revenue.
The Rhode Island-based pharmacy operator also raised its full-year EPS guidance to $3.32 to $3.38, versus the analysts’ consensus estimate of $3.32 per share.
Revenues in the Retail Pharmacy Segment increased 6.9% to $15.8 billion, with same-store sales 5.6% higher year over year. CVS benefited from competitor Walgreen Co. (NYSE: WAG) not being part of the Express Scripts Holding Co. (NASDAQ: ESRX) pharmacy provider network during the quarter. Walgreen will reenter that network in September.
CVS also said revenues in the Pharmacy Services Segment increased 28.2% to $18.4 billion, driven in part by new activity resulting from the acquisition of the Medicare prescription drug plan of Universal American Corp.
“We delivered results that were at or above our expectations in both the retail and PBM segments,” said Larry Merlo, president and CEO. “With our stable business and differentiated offerings, we remain very well positioned in the marketplace.”
Shares are up by 1.9% in premarket trading at $45.75, and the 52-week trading range is $31.30 to $48.69. Thomson Reuters had a consensus analyst price target of $50.95 before this news.
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.